Table 3 Clinical trials for HPV-associated cancer
From: Immunologic treatments for precancerous lesions and uterine cervical cancer
Vaccine | Antigen(s) | Phase | Cancer |
|---|---|---|---|
ADXS11-001: | HPV-16 | I | Cervical cancer |
Lm secreting fusion to LLO- HPV- 16 E7 protein (Lm- LLO- E7) | E7 | I | HPV- oropharyngeal cancer |
II | Recurrent cervical carcinoma | ||
TA-HPV: Recombinant vaccinia virus expressing E6 and E7 from both HPV- 16 and HPV- 18 | E6 and E7 of HPV16 and HPV-18 E6 | I | Stage Ib and IIa cervical cancer |
I/II | Advanced cervical cancer | ||
II | Stage Ib and IIa cervical cancer | ||
PADRE peptide linked to E7 Lipopeptide | HPV-16 E7 | I | Cervical cancer |
HPV- 16 E7 epitopes emulsified in Montanide ISA- 51 adjuvant | HPV-16 E7 | I/II | Cervical cancer |
13 overlapping long peptides covering whole E6 and E7 sequences of HPV 16 plus Montanide ISA- 51 adjuvant | HPV-16 E6 and E7 | I | Advanced cervical cancer stage Ib1 cervical cancer |
II | |||
DC pulsed with HPV- 16 E7 | HPV-16 E7 | I | Recurrent cervical cancer |
pNGVL4a- Sig/ E7/ Hsp70: DNA plasmid expressing mutated HPV- 16 E7 fused to Sig and Hsp70 | HPV-16 E7 | I | Advanced HNSCC |